Financial reports
10-Q
2024 Q2
Quarterly report
13 Feb 24
10-K/A
2023 FY
Annual report (amended)
21 Dec 23
10-Q
2024 Q1
Quarterly report
13 Nov 23
10-K
2023 FY
Annual report
29 Sep 23
NT 10-K
Notice of late annual filing
29 Sep 23
10-Q
2023 Q3
Quarterly report
15 May 23
10-Q
2023 Q2
Quarterly report
17 Feb 23
NT 10-Q
Notice of late quarterly filing
9 Feb 23
10-Q
2023 Q1
Quarterly report
14 Nov 22
10-K/A
2022 FY
Annual report (amended)
28 Sep 22
Current reports
8-K
Regulation FD Disclosure
18 Apr 24
8-K
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
16 Apr 24
8-K
Regulation FD Disclosure
5 Apr 24
8-K
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
20 Mar 24
8-K
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
13 Feb 24
8-K
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
9 Feb 24
8-K
Regulation FD Disclosure
19 Jan 24
8-K
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
16 Jan 24
8-K
InMed Announces Results of 2023 Annual General Meeting
19 Dec 23
8-K
Regulation FD Disclosure
29 Nov 23
Registration and prospectus
S-8
Registration of securities for employees
21 Dec 23
424B3
Prospectus supplement
13 Nov 23
S-1
IPO registration
8 Nov 23
424B3
Prospectus supplement
15 Dec 22
S-1
IPO registration
7 Dec 22
D
$6.00 mm in equity / options, sold $6.00 mm, 2 investors
5 Dec 22
S-8
Registration of securities for employees
14 Nov 22
424B3
Prospectus supplement
19 Oct 22
S-1
IPO registration
11 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Sep 22
Other
EFFECT
Notice of effectiveness
14 Nov 23
UPLOAD
Letter from SEC
10 Nov 23
CORRESP
Correspondence with SEC
9 Nov 23
EFFECT
Notice of effectiveness
15 Dec 22
CORRESP
Correspondence with SEC
12 Dec 22
UPLOAD
Letter from SEC
12 Dec 22
EFFECT
Notice of effectiveness
19 Oct 22
CORRESP
Correspondence with SEC
14 Oct 22
UPLOAD
Letter from SEC
14 Oct 22
EFFECT
Notice of effectiveness
11 Oct 22
Ownership